Trial Profile
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hepatic encephalopathy; Hyponatraemia
- Focus Therapeutic Use
- 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 Mar 2014 New trial record